Tiffany Liu, MD
Neurology · Lafayette, LANPI 1558705012
Payments from drug & device makers
Across 286 payments — averaging $35.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- EMD Serono, Inc.$3K
- AbbVie$708
- UCB, Inc.$569
- AstraZeneca$535
- Amgen$400
- plus $2K from 31 others
What the payments were for
- Consulting fees$1,97519%
- Speaking & faculty fees$3664%
- Food & beverage$4,83948%
- Education$2693%
- Gifts$2,73327%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $2,902 |
| EMD Serono, Inc. | 24 | $2,794 |
| AbbVie(2 entities) | 43 | $708 |
| UCB, Inc. | 16 | $569 |
| AstraZeneca | 8 | $535 |
| Amgen(2 entities) | 21 | $400 |
| Sunovion Pharmaceuticals Inc. | 36 | $322 |
| Acadia Pharmaceuticals Inc | 24 | $275 |
| Lilly USA, LLC | 10 | $185 |
| SK Life Science, Inc. | 8 | $169 |
| Teva Pharmaceuticals USA, Inc. | 14 | $162 |
| Neurocrine Biosciences, Inc. | 9 | $160 |
| Sanofi | 8 | $141 |
| Eisai Inc. | 8 | $136 |
| Neurelis, Inc. | 3 | $67 |
| Medtronic(2 entities) | 2 | $67 |
| Avanir Pharmaceuticals, Inc. | 4 | $59 |
| Amneal Pharmaceuticals LLC | 4 | $56 |
| Lundbeck LLC | 3 | $50 |
| Adamas Pharmaceuticals, Inc. | 3 | $49 |
| Zyla Life Sciences, Inc. | 2 | $38 |
| Genentech USA, Inc. | 2 | $35 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Kyowa Kirin, Inc. | 2 | $29 |
| Upsher-smith Laboratories LLC | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| CSL Behring | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $16 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| MDD US Operations, LLC | 1 | $15 |
| Biogen | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
| Catalyst Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,182 in reported general payments places this provider in the 70th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 20 | $106,341 |
| Kesimpta PenOfatumumab | 12 | $98,003 |
| XcopriCenobamate | 51 | $92,702 |
| CopaxoneGlatiramer Acetate | 16 | $84,817 |
| RytaryCarbidopa/Levodopa | 35 | $50,768 |
| Nurtec OdtRimegepant Sulfate | 29 | $34,791 |
| AptiomEslicarbazepine Acetate | 19 | $19,071 |
| UbrelvyUbrogepant | 19 | $17,128 |
| DepakoteDivalproex Sodium | 12 | $14,761 |
| Rasagiline Mesylate | 12 | $9,711 |
| Levetiracetam | 211 | $7,426 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 19 | $5,713 |
| Lacosamide | 53 | $4,699 |
| Azathioprine | 33 | $3,946 |
| Carbamazepine ErCarbamazepine | 42 | $3,735 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $275 | $106,34120 claims |
| SK Life Science, Inc.Xcopri | $169 | $92,70251 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $162 | $84,81716 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $56 | $53,49077 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $322 | $19,07119 claims |
| AbbVieUbrelvy | $708 | $17,12819 claims |
| Upsher-smith Laboratories LLCTopiramate | $29 | $92574 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 225 neurology providers in Louisiana.
Other neurology in Lafayette
- Oliver AchiLafayette$187K
- Fabian LugoLafayette$27K
- Kevin HargraveLafayette$21K
- Virginia KellnerLafayette$18K
- Sahil ThankiLafayette$18K
- Steven SnaticLafayette$15K
- Thomas PrivettLafayette$15K
- Adam ForemanLafayette$12K
- Ariel Antezana AntezanaAlexandria$2.5M
- Jon OlsonBaton Rouge$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.